MOST NOTEWORTHY: Mako Surgical, ArcSight and ICU Medical were today's noteworthy initiations:
- Mako Surgical (NASDAQ: MAKO) was initiated with an Overweight rating at JP Morgan. The firm believes Mako has the most compelling system for navigated, robotic assisted orthopedic surgery to date.
- After ArcSight (NASDAQ: ARST) reported better-than-expected results for its Q3 and guidance for Q4 that Wachovia views as positive, the firm, which initiated shares with an Outperform rating, expects that regulatory compliance initiatives such as SOX will help protect the company from the slowdown, and help result in upward revisions to Wachovia's estimates in the future, as well as margin expansion.
- Soleil believes ICU Medical's (NASDAQ: ICUI) close distributor relationship with Hospira (NYSE: HSP) will drive its CLAVE/Custom IV franchises. The firm started shares with a Buy rating and $33 target.
OTHER INITIATIONS:
- Bear initiated Journal Comm (NYSE: JRN) with an Outperform rating and $10.25 target.
- Royal KPN (NYSE: KPN) was initiated at Societe Generale with a Sell rating.
- Broadpoint assumed Nuance Comm (NASDAQ: NUAN) with a Buy rating and $22 target.
5-Hour Energy: A Success Equal Parts Caffeine, Chemistry and…
Suddenly, Amazon Doesn't Love Its Moms Anymore
I'm pregnant, with my third child, and the ultrasound gods did not smile upon me. So whereas I was able to select my previous sons' names (Everett, a family name, and Truman, a presidential name that was distinguished by being both unusual and easily pronounceable) by the time I hit five months, with this baby, I'm lost in a sea of uncertainty -- and I only have a little more than two months to go. I have a girl's name, but for boys, what to do?

